Results 21 to 30 of about 8,627 (176)

Translation of a physiologically-based pharmacokinetic model for dabigatran etexilate to the design of a safety and efficacy study in post-partum women. [PDF]

Br J Clin Pharmacol
Aims To translate a PBPK model developed for the direct oral anticoagulant, dabigatran etexilate, the prodrug of dabigatran, based on data obtained from healthy men to healthy non‐pregnant, pregnant and post‐partum women. To evaluate safety and efficacy of dabigatran etexilate in post‐partum women using simulations and design a future clinical study to
Ogungbenro K, Aucott L, Kamali F, Ayuk P.   +3 more
europepmc   +2 more sources

Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects

Pharmaceuticals, 2023
Higher risk of major hemorrhage associated with concomitant use of dabigatran and simvastatin compared to other statins was previously reported with a suggestion of P-glycoprotein-mediated interaction. The aim of this study was to evaluate the effects of
Hyewon Chung, Jong-Min Kim, Jin-Woo Park, Jihyeon Noh, Kyoung-Ah Kim, Ji-Young Park   +5 more
doaj   +1 more source

Geographical variability in dabigatran dosing within New Zealand. [PDF]

Intern Med J
Abstract Dabigatran etexilate is an oral anticoagulant with increased risk of bleeding at high drug exposure. It is available in three capsule strengths (75, 110 and 150 mg). We analysed New Zealand dispensing data from 2019 to 2023 to compare use between health districts. Overall use was similar across districts.
Berryman LT, Chin PKL, Pairman LJ, Sundermann M, Doogue M.   +4 more
europepmc   +2 more sources

Dabigatran in Cerebral Sinus Vein Thrombosis and Thrombophilia

Life, 2022
Background and Purpose: Thrombophilic gene alterations are a major risk factor for cerebral sinus vein thrombosis (CSVT). Up to 30% of all patients with cerebral sinus vein thrombosis (CSVT) are found to have thrombophilic defects such as prothrombin ...
Lukas Kellermair, Matthias W. G. Zeller, Caterina Kulyk, Josef Tomasits, Tim J. von Oertzen, Milan R. Vosko   +5 more
doaj   +1 more source

Therapeutic potential of small molecules that block receptor-induced Kv7/M-current suppression in neuroprotection, seizures, and pain. [PDF]

Br J Pharmacol
Receptor‐induced Kv7/M‐current suppression increases neuronal activity and contributes to pathology of several conditions. A new class of Kv7 modulators identified in this study attenuates M‐current suppression and shows therapeutic effects. Abstract Background and Purpose Neuronal Kv7 channels generate low voltage–gated potassium currents known as the
Kim YW, Behara PK, Alhassen L, Wong C, Civelli O, Hoshi N.   +5 more
europepmc   +2 more sources

PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

Рациональная фармакотерапия в кардиологии, 2015
According to recent guidelines, oral dabigatran etexilate is indicated for stroke and systemic embolism prevention in patients with atrial fibrillation (AF). Aim.
Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov   +3 more
doaj   +3 more sources

Dabigatran etexilate and COVID-19

, 2021
Thrombotic complications are frequent in COVID-19. There is evidence supporting the use of prophylactic dose low molecular weight heparin (LMWH) as prophylaxis for venous thromboembolism in critically ill patients. Indeed, all patients with COVID-19 that
Domina Petric
core   +1 more source

No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke [PDF]

, 2012
Background: Dabigatran etexilate (DE) is a new oral direct thrombin inhibitor. Clinical trials point towards a favourable risk-to-benefit profile of DE compared to warfarin. In this study, we evaluated whether hemorrhagic transformation (HT) occurs after
Ferdinand Bohmann, Christian Foerch (149410), Edelgard Lindhoff-Last (149408), Ferdinand Bohmann (149406), Mirceska, Ana, Ana Mirceska, Förch, Christian, Waltraud Pfeilschifter, Pfeilschifter, Josef (Prof. Dr.), Bohmann, Ferdinand, Edelgard Lindhoff-Last, Waltraud Pfeilschifter (149411), Helmuth Steinmetz, Steinmetz, Helmuth, Christian Foerch, Helmuth Steinmetz (149409), Pfeilschifter, Waltraud, Josef Pfeilschifter, Josef Pfeilschifter (92946), Ana Mirceska (149407), Lindhoff-Last, Edelgard   +20 more
core   +2 more sources

Thrombolysis in a stroke patient on dabigatran anticoagulation: case report and synopsis of published cases [PDF]

, 2013
We present the case of an aphasic 77-year-old stroke patient with left distal M1 occlusion who received rt-PA for thrombolysis while on oral anticoagulant treatment with dabigatran (150 mg b.i.d.).
Baas, Horst, Mario Abruscato, Susanne Hövelmann, Pfeilschifter, Waltraud, Abruscato, Mario Giovanni Rosario, Hövelmann, Susanne, Horst Baas, Waltraud Pfeilschifter   +7 more
core   +1 more source

Determination of Dabigatran Concentration in Human Plasma and Breast Milk

International Journal of Analytical Chemistry, 2021
Venous thromboembolism (VTE) is an important cause of death following childbirth. Dabigatran etexilate can be a useful prophylaxis in susceptible women during the postpartum period. However, it is not clear whether dabigatran is excreted into breast milk
F. Sidgwick, A. Porter, P. Ayuk, F. Kamali, A. Truemann   +4 more
doaj   +1 more source